Two-Year psoriasis treatment trial seeks to prove lasting relief
NCT ID NCT07449702
Summary
This study aims to learn about the long-term safety and effectiveness of an investigational medication called ORKA-001 for adults with moderate-to-severe plaque psoriasis. It is open only to people who have already taken ORKA-001 in a previous company-sponsored study. Participants will receive the medication for up to about two years, followed by nearly a year of follow-up monitoring.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PLAQUE PSORIASIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Oruka Therapeutics Investigative Site
RECRUITINGLos Angeles, California, 90045, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Oruka Therapeutics Investigative Site
RECRUITINGSan Diego, California, 92123, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Oruka Therapeutics Investigative Site
RECRUITINGCoral Gables, Florida, 33134, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Oruka Therapeutics Investigative Site
RECRUITINGBowling Green, Kentucky, 42104, United States
Contact Email: •••••@•••••
-
Oruka Therapeutics Investigative Site
RECRUITINGRockville, Maryland, 20850, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Oruka Therapeutics Investigative Site
RECRUITINGPeterborough, Ontario, K9J 5K2, Canada
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.